查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1562499

癌症免疫疗法市场规模、份额、成长分析、按产品类型、按应用、按最终用户、按地区 - 行业预测，2024-2031

Cancer Immunotherapy Market Size, Share, Growth Analysis, By Product Type (Monoclonal Antibodies, Vaccines), By Application (Breast Cancer, Lung Cancer), By End User (Hospitals, Clinics & Others), By Region - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年，全球癌症免疫治疗市场规模为1,254亿美元，从2023年的1,359.3亿美元成长到2031年的2,591.6亿美元，预计在预测期内（2024-2031年）将成长。为8.4%。

由于几个关键因素，预计全球癌症免疫治疗市场将在预测期内显着增长。相对于传统治疗方法，向标靶治疗的转变，加上对单株抗体 (mAB) 的需求不断增加以及世界各地各种生物相似药的推出，预计将推动市场扩张。这些创新药物旨在增强人体的免疫反应来对抗癌症，并在很大程度上依赖新的分子发现。预计这一趋势将对未来几年的市场成长和需求产生积极影响。此外，市场也可能受益于美国食品药物管理局（FDA）等监管机构核准的增加。例如，PD-1和CTLA-4查核点抑制剂的核准用于治疗黑色素瘤和非小细胞肺癌（NSCLC）预计将进一步推动市场成长。一个着名的例子是 FDA核准Amgen 的 Lumaclas。该药物针对患有与局部进行性或转移性 NSCLC 相关的 KRAS G12C 突变的患者，作为该疾病的首个治疗方法代表了突破。这些进步支撑了癌症免疫治疗市场不断成长的商机。

目录

介绍

  • 研究目的
  • 定义
  • 市场范围

调查方法

  • 资讯采购
  • 二手资料来源和主要资料来源
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 市场概况展望
  • 供需趋势分析
  • 按细分市场的机会分析

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 波特的分析

主要市场考察

  • 技术分析
  • 价格分析
  • 价值链分析
  • 市场生态系统
  • 贸易分析
  • 供应链分析
  • 案例研究分析
  • 专利分析
  • 客户和购买标准分析
  • 监管环境
  • 创新矩阵
  • 主要投资分析
  • 关键成功因素
  • 竞争程度

癌症免疫治疗市场：依产品类型

  • 市场概况
  • 单株抗体
    • 裸单株抗体
    • 结合单株抗体
    • 双特异性单株抗体
  • 疫苗
    • 预防性疫苗
    • 治疗性疫苗
  • 查核点抑制剂
    • 细胞毒性 T 淋巴球相关蛋白 4 (CTLA-4)
    • 程序性细胞死亡 1 (PD-1) 和程序性细胞死亡配体 1 (PD-L1)
  • 细胞疗法
    • 嵌合体抗原受体 (CAR) T 细胞疗法
    • 树突状细胞
  • 免疫调节剂
    • 粒细胞巨噬细胞集落刺激因子（Gm-Csf 和 G-Csf）
    • 干扰素(IFN)
    • 白细胞介素(IL)
    • 溶瘤病毒
    • 免疫疗法
    • 免疫是一种疾病
    • 作为盟友的免疫力
    • 核准的产品和临床试验

癌症免疫治疗市场：依应用分类

  • 市场概况
  • 肺癌
  • 乳癌
  • 多发性骨髓瘤
  • 大肠直肠癌
  • 头颈癌
  • 摄护腺癌
  • 恶性黑色素瘤
  • 其他癌症类型

癌症免疫治疗市场：依最终用户分类

  • 市场概况
  • 医院
  • 诊所/其他

癌症免疫治疗市场规模：按地区划分

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位（2023年）
  • 主要市场参与者所采取的策略
  • 近期市集活动
  • 主要企业市场占有率（2023年）

主要企业简介

  • Amgen Inc.（US）
  • AstraZeneca（UK/Sweden）
  • Bayer AG（Germany）
  • Bristol-Myers Squibb（US）
  • Eli Lilly and Company（US）
  • Janssen Global Services, LLC（Johnson & Johnson）（US）
  • Merck & Co., Inc.（US）
  • Novartis（Switzerland）
  • Pfizer Inc.（US）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Gilead Sciences, Inc.（US）
  • GlaxoSmithKline plc（UK）
  • AbbVie Inc.（US）
  • Regeneron Pharmaceuticals, Inc.（US）
  • Adaptimmune Therapeutics plc（UK）
  • Incyte Corporation（US）
  • Bluebird bio, Inc.（US）
  • BioNTech SE（Germany）
  • Immunocore Limited（UK）
  • CureVac NV（Germany）
  • BeiGene, Ltd.（China）
  • Zymeworks Inc.（Canada）
简介目录
Product Code: SQMIG35I2296

Global Cancer Immunotherapy Market size was valued at USD 125.4 billion in 2022 and is poised to grow from USD 135.93 billion in 2023 to USD 259.16 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2024-2031).

The global market for cancer immunotherapy is projected to experience significant growth during the forecast period, driven by several key factors. The shift towards targeted therapies over traditional treatments, coupled with the increasing demand for monoclonal antibodies (mABs) and the introduction of various biosimilars worldwide, is expected to propel market expansion. These innovative drugs are designed to enhance the body's immune response to combat cancer, relying heavily on the discovery of new molecules. This trend is anticipated to positively impact market growth and demand in the coming years. Additionally, the market is set to benefit from growing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA). For example, the approval of PD-1 and CTLA-4 checkpoint inhibitors for treating melanoma and non-small cell lung cancer (NSCLC) is expected to further drive market growth. A notable instance is the FDA's approval of Amgen's LUMAKRAS. This drug, designed for patients with KRAS G12C mutation associated with locally advanced or metastatic NSCLC, represents a groundbreaking development as it is the first-ever treatment for this condition. Such advancements underscore the expanding opportunities within the cancer immunotherapy market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Immunotherapy Market Segmental Analysis

Global Cancer Immunotherapy Market is segmented by Product Type, Application, End user, and region. Based on Product Type, the market is segmented into Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma, and Other Cancer Types. Based on End user, the market is segmented into Hospitals, and Clinics & Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Cancer Immunotherapy Market

The growing preference for immunotherapy over traditional treatments like radiation therapy and chemotherapy is expected to significantly drive the global cancer immunotherapy market in the coming years. Unlike radiation and chemotherapy, which primarily aim to destroy cancer cells through irradiation or surgery, these conventional methods often have the drawback of damaging healthy cells as well. This limitation has led to an increasing shift towards immunotherapy, which works by enhancing the body's own immune system using engineered proteins to target cancer cells more precisely. As a result, hospitals and surgical centers are increasingly adopting immunotherapy treatments due to their potential to reduce side effects and improve patient outcomes. This shift in treatment preference is fostering substantial growth in the global cancer immunotherapy market. By leveraging the body's natural defenses, immunotherapy offers a promising alternative that aligns with the evolving needs of healthcare providers and patients, thereby driving market expansion.

Restraints in the Global Cancer Immunotherapy Market

The high manufacturing costs and elevated prices of cancer immunotherapy treatments are significant factors that may impede the growth of the global market in the forecast period. The development and enhancement of these therapies require substantial resources and significant investment, which can slow market expansion. Additionally, limited medical access in remote and underserved areas, along with geographical barriers, could further restrict the awareness and availability of cancer immunotherapies. These challenges contribute to the slower adoption of these advanced treatments, potentially affecting overall market growth.

Market Trends of the Global Cancer Immunotherapy Market

Ongoing research into drugs designed to minimize side effects is anticipated to stimulate market growth. Additionally, the approval of PD-1 and CTLA-4 checkpoint inhibitors for treating melanoma and Non-Small Cell Lung Cancer (NSCLC) has significantly contributed to the market's expansion. The introduction of new forms of immunotherapy, including vaccines and adjuvants, is further fueling this growth. Moreover, the development and testing of additional immunotherapies, such as immunomodulators and CAR T-cell therapies, are showing promise for improving treatment outcomes. These advancements, coupled with new drug approvals, are expected to drive substantial growth in the cancer immunotherapy market throughout the forecast period.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • Trade Analysis
  • Supply chain Analysis
  • Case study Analysis
  • Patent Analysis
  • Customer & Buying Criteria Analysis
  • Regulatory Landscape
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Cancer Immunotherapy Market by Product Type

  • Market Overview
  • Monoclonal Antibodies
    • Naked Monoclonal Antibodies
    • Conjugated Monoclonal Antibodies
    • Bispecific Monoclonal Antibodies
  • Vaccines
    • Prophylactic Vaccines
    • Therapeutic Vaccines
  • Checkpoint Inhibitors
    • Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
    • Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)
  • Cell Therapies
    • Chimeric Antigen Receptor (CAR) T Cell Therapy
    • Dendritic Cells
  • Immunomodulators
    • Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf)
    • Interferons (IFN)
    • Interleukins (IL)
    • Oncolytic Virus
    • Immunotherapy
    • Immunity as an Obstacle
    • Immunity as an Ally
    • Approved Products & Clinical Trails

Cancer Immunotherapy Market by Application

  • Market Overview
  • Lung Cancer
  • Breast Cancer
  • Multiple Myeloma
  • Colorectal Cancer
  • Head & Neck Cancer
  • Prostate Cancer
  • Melanoma
  • Other Cancer Types

Cancer Immunotherapy Market by End User

  • Market Overview
  • Hospitals
  • Clinics & Others

Cancer Immunotherapy Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Amgen Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK/Sweden)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Janssen Global Services, LLC (Johnson & Johnson) (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneron Pharmaceuticals, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Adaptimmune Therapeutics plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Incyte Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bluebird bio, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioNTech SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Immunocore Limited (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CureVac N.V. (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BeiGene, Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zymeworks Inc. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments